ArticleSurgical endoscopy2026
Potential role of a synthetic peptide hydrogel in accelerating mucosal defect healing: evidence from a porcine model.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A pilot study on the efficacy of cyanoacrylate glue in preventing post-ESD bleeding at the gastric angle.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing use of advanced endoscopic resection techniques, including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), brings significant post-procedural challenges, particularly delayed bleeding and impaired wound healing. This study aimed to evaluate the efficacy of PuraStat, a synthetic peptide hydrogel, in promoting mucosal healing following endoscopic resections in the oesophagus and stomach of a porcine model.
methodsIn this prospective, randomised, evaluator-blinded preclinical study, 21 pigs underwent EMR and ESD in both the oesophagus and stomach (2 EMR and 2 ESD per animal). Animals were randomised to receive either PuraStat or saline on each resection site. Healing was evaluated after 8 days using follow-up endoscopy, gross pathology, and histopathological analysis. The primary endpoint was re-epithelialisation-to-defect ratio; secondary outcomes included macroscopic wound size reduction and granulation tissue characteristics.
resultsA total of 84 lesions were assessed. Lesions treated with PuraStat demonstrated significantly greater re-epithelialisation/defect ratios compared to controls (p = 0.03), particularly after EMR. Endoscopic evaluation demonstrated a 33% mean reduction in wound size in the PuraStat group (p = 0.001). However, as endoscopic measurements carry an estimated error margin of up to ± 10%, its precision may be limited. Histopathological analysis of post-resection defect area reduction did not show statistically significant difference between groups (p = 0.055). No adverse events were observed, and PuraStat was well tolerated.
conclusionsApplication of PuraStat hydrogel after endoscopic resections was associated with improved re-epithelialisation, particularly in EMR-induced lesions. These findings indicate potential role of PuraStat in support of healing of mucosal post-resection defects in upper gastrointestinal tract, warranting its further validation in clinical trials.
Indexed as
Identifiers
41326730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.